Abstract
Thomas Bollyky explains the emerging controversy over patented medicines for noncommunicable diseases and their affordability in developing countries. Another transformation in global health is required that focuses on low-cost interventions and patient-centered, rather than country-focused, strategies. Please see later in the article for the Editors' Summary